Review Articles

Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis

Susanne A. Gatz, MD, PhD, FRCPCH[1,2]; Julia Glade-Bender, MD[3]; Andrew D.J. Pearson, MBBS, MD, DCH[4]; Michael V. Ortiz, MD[3]; Ronald Bernardi, PhD[5]; Lou Chesler, MD, PhD[6]; Steve Clifford, PhD[7]; Sarah Cohen-Gogo, MD, PhD[8]; Esther De La Cuesta, MD, MBA[9]; Teresa de Rojas, MD, PhD[4]; Kaat Durinck, PhD[10,11]; Sara Federico, MD[12]; Elizabeth Fox, MD[12]; Sally George, MBBS, PhD[6,13]; Ioannis Gounaris, MD, PhD[14]; Anton George Henssen, MD[15]; Meredith Irwin, MD[8]; Marcel Kool, PhD[16,17,18,19]; Alan Lau, PhD[20]; Karsten Nysom, MD, PhD[21]; Alberto Pappo, MD[12]; Gregory K. Pennock, MD[22]; Stefan M. Pfister, MD[23]; Nicole Scobie[4]; Emily K. Slotkin, MD[3]; Malcolm Smith, MD, PhD[24]; Frank Speleman, PhD[10,11]; Elizabeth A. Stewart, MD[12]; Brenda J. Weigel, MD, MSc[12]; and Gilles Vassal, MD, PhD[4,25]

ABSTRACT

PURPOSE High levels of DNA replication stress and defects in the DNA damage response (DDR) pathways are vulnerabilities of many poor prognosis childhood malignancies. Ataxia telangiectasia and Rad3-related protein (ATR) is a key regulator of these pathways and constitutes an attractive target, especially in combination. However, the malignancies where ATR inhibitors have maximum benefit and synergistic combinations differ between adults and children.

DESIGN ACCELERATE convened a multistakeholder meeting and conducted review and analysis to propose the optimal pathway for the development of ATR inhibitors in pediatric malignancies.

RESULTS Considering the lack of identified biomarkers, the initial evaluation of ATR inhibitors should focus on Ewing sarcoma, rhabdomyosarcoma, and neuroblastoma in view of their high levels of DNA replication stress and defects in DDR pathways. Early phase trials of ATR inhibitors should be iterative, based on a clear hypothesis with responders and nonresponders undergoing detailed molecular analysis and a revised new hypothesis generated. Trial designs should restrict monotherapy evaluation to a brief exposure in a small number of patients and progress rapidly to combinations. Highlighted combination partners are poly(ADP-ribose) polymerase inhibitors and antibody drug conjugates with topoisomerase I inhibitor payloads. Combinations with ALK inhibitors (in *ALK/MYCN*-aberrant neuroblastoma) and aurora A kinase (in *MYCN*-amplified) are supported by robust mechanisms of action and preclinical data. Early interactions with regulators are crucial, and early phase clinical trials should be conducted in regulatory-approved, academic-sponsored, industry-supported, platform trials.

CONCLUSION ATR inhibitors are a prototype for the development of medicinal products in a limited pediatric population. For the substantial potential of ATR inhibitors in children with malignancy to be realized, strategic planning between academia, industry, regulators, and patient advocates is vital.

INTRODUCTION

High levels of DNA replication stress and defects in the DNA damage response (DDR) pathways, which are critical for maintaining genomic integrity,[1,2] are vulnerabilities of many poor prognosis childhood malignancies.[3-9] Ataxia telangiectasia and Rad3-related protein (ATR) is a key regulator of the DDR machinery and functions in the replication stress response.[1] ATR is an attractive therapeutic target holding significant promise, and several ATR inhibitors (ATRi) are undergoing clinical studies in adults,[1] but no drugs are approved. Although the class of drugs has potential benefit for children with cancer, especially in combination, there are many aspects regarding their development which are unclear. Moreover, there are challenges in evaluating multiple new products in rare populations, making it of value to identify for ATRi: (1) the optimal diseases and/or biomarker-defined populations; (2) the value of monotherapy trials and

best clinical trial design; (3) the most beneficial combinations; and (4) the best approach to a coordinated and integrated drug development strategy of available assets, in the context of the population size.

To address these issues, ACCELERATE, an international multistakeholder organization, whose objective is to advance the timely investigation of new anticancer drugs,[10,11] convened multistakeholder meetings following the Paediatric Strategy Forum on DDR pathway inhibitors.[12] This is a review and analysis of the issues identified and proposed potential solutions focused on ATRi.

THE ROLE OF ATR IN DDR

ATR is a mediator of the cellular replication stress response, which regulates the activation of cell cycle checkpoints and DNA replication to control cell division and safeguard genomic integrity, and is a member of the phosphatidylinositol 3-kinase-related kinase (PI3-K) family, which includes DNAPK and ATM.[13-16] The ATR-CHK1-CDC25C-CDK1 pathway preferentially responds to replication-associated damage in S and G2/M to inhibit cell cycle progression into mitosis. ATR principally senses, and is activated by, the presence of extensive single-stranded DNA (ssDNA) at sites of stalled replication forks or single-strand breaks incurred from other sources of DNA damage.[17-21] On activation, ATR initiates a cascade of coordinated downstream reactions that lead to arrest of cell cycle progression and stabilization of stalled replication forks, thus enabling DNA repair.[6,21] The ATR-CHK1 signaling pathway acts as an important rheostat in normal cells, but cancer cells can become addicted to this pathway because of oncogene-induced enhanced replicative stress.[22-24] These replication events lead to increased levels of fork stalling and collapse, resulting in increased ssDNA and toxic double-strand DNA breaks. Cancer cells may also acquire increased dependency on co-occurrent loss or inactivation of other key components of the DDR machinery[4] and are potentially susceptible to synthetically lethal combinations. For example, poly(ADP-ribose) polymerase (PARP) plays a key role in the repair of ssDNA. PARP inhibitors (PARPi) have demonstrated clinically relevant synthetic lethality in patients with breast cancer harboring DDR pathway alterations, most commonly BRCA1 or BRCA2 mutations.[25,26] However, PARPi can also trap PARP1/2 at sites of DNA damage, leading to stalled replication forks and augmenting replication stress requiring ATR for resolution; coincidently, ATR inhibition can suppress homologous recombination repair (HRR) potentially sensitizing cells to PARPi.[27,28] ATM preferentially responds to and repairs DNA double-strand breaks, inhibits cell cycle progression into S-phase, and represents a complementary mechanism to ATR-mediated DDR; thus, loss of ATM may also result in synthetic lethality during ATR inhibition. ATR plays an important role in development, and ATR deficiency during embryogenesis results in high levels of replicative stress and accelerated aging.[29] Furthermore, the ATR to ATM signaling axis plays a role in the maintenance of telomere homeostasis and the surveillance of telomere dysfunction during neurogenesis.[30,31]

ATR INHIBITORS IN ADULT ONCOLOGY

Clinical trials of six ATR kinase inhibitors (berzosertib,[32,33] ceralasertib,[34-36] elimusertib,[37,38] camonsertib,[39,40] tuvusertib,[41] and ART0380[42]) have been conducted, with berzosertib and elimusertib being discontinued because of the lack of activity. ATRi are generally tolerable with myelosuppression, particularly anemia, and nausea being the most clinically relevant toxicities in adults.

Generally, data from phase I dose-escalation cohorts of unselected adult patients with advanced-stage cancer indicate limited efficacy of ATRi as monotherapies.[41-44] No single integral biomarker of sensitivity to ATRi has been established; potential biomarkers studied include individual genomic alterations that predispose to HRR deficiency and measurements of replication stress accumulation, including gene signatures and functional assays.[1,28,40] Phase I single-agent trials, which specifically recruited patients with advanced-stage solid tumors harboring DDR defects, reported higher overall response rates.[39-41,45] An early phase trial of camonsertib used a chemogenomic screen for DDR alterations across approximately 100 genes to identify patients for enrollment and demonstrated both response and meaningful clinical benefit across multiple histologies.[40] In addition, preclinical investigation demonstrated that in vitro models of ATM loss malignancies (either ATM mutation or protein loss) are very sensitive to ATR inhibition.[46,47] Accordingly, the phase I trial of elimusertib in adults focused on patients with ATM aberrations and showed partial responses in patients whose tumors lacked detectable ATM protein expression. Unfortunately, this signal could not be confirmed in the expansion cohorts.[45] ATRi delaying or overcoming resistance to PARP[48] and in combination with immune checkpoint inhibitors[49,50] are being explored.

ATR INHIBITORS IN CHILDREN

Biomarkers for ATR inhibitor activity in children are likely to be different compared with that in adults. Generally, in pediatric cancer, there are a relative lack of mutations and a prominence of copy number aberrations, for example, 11q deletion.[51] For example, loss of HRR genes, especially biallelic loss, is exceedingly rare in pediatric tumors, as are mutations of BRCA1 and BRCA2 and ATM (<1%).[51-55] Loss of function of ATM and the role of ATM mutations or ATM protein expression have been problematic to determine[37,45] because of (1) the difficulty in predicting whether a specific mutation is deleterious or a variant of uncertain significance,[56] (2) the zygosity of the alteration which may affect the loss of protein function,[57] and (3) nonharmonized immunohistochemistry protocols.

Although the most discriminatory predictive biomarkers for ATRi in pediatric malignancies are unknown, there are

biological changes in pediatric malignancy which have been related to the activity of ATRi: *ATM* deletion because of 11q loss[58]; *MYCN/MYC* amplification[59-61]; aberrant transcription factor gene fusion (*PAX3-FOXO1*,[7,62] *EWSR1-FLI*[3,63]); epigenetic modifier gene fusions (*SS18-SSX1/2*); *ATRX* mutation/loss; *STAG2* mutation; *SETD2* mutation/loss; *CHEK1/gH2AF*, *MRE11A* loss; histone mutations (H3K27, H3K36); *TP53* mutations; and alternative lengthening of telomeres (ALT). ALT is an independent mechanism of telomere maintenance, in the absence of direct telomerase activation because of high telomerase reverse transcriptase (TERT) expression.[64] Preclinical reports of the relevance of ALT as a biomarker of ATR inhibitor activity are conflicting,[65-68] and ALT-positive neuroblastoma displays skewed sensitivity for ATM versus ATR inhibition.[69]

Ongoing trials in pediatrics are evaluating ceralasertib[69-74] and elimusertib[75,76] (Table 1):

1. A phase I/II study Bay 18953444 (elimusertib) in pediatric patients with relapsed or refractory solid tumors (PEPN2112).[75,76] This study is based on preclinical data demonstrating that Ewing sarcoma and fusion-positive rhabdomyosarcoma are susceptible to in vitro and in vivo ATR inhibition.[3,4,7]

2. Arm N of ESMART[69-76] uses the PARPi, olaparib, with ceralasertib. Tumors have advanced molecular profiling (whole-exome sequencing or whole-genome sequencing [WGS] with or without RNA sequencing) allowing for both enrichment of patients with certain molecular features and detailed retrospective molecular analyses of responders and nonresponders. Eligibility for cohort 1 is HRR deficiency with a focus on *ATM* alterations, and that for cohort 2 is increased replication/transcription stress including transcription factor fusions and amplifications.

3. Olaparib with ceralasertib in recurrent osteosarcoma[72-74] was recently completed. Only one of 37 patients had an objective response. Data analysis is ongoing.

A PLAN FOR THE INCLUSION OF BIOMARKERS IN CLINICAL TRIALS

At the Paediatric Strategy Forum on DDR pathway inhibitors, the disparity of assessments to identify biomarkers for ATRi hindered a comparison between the results generated between clinical trials.[12] It was concluded that "an integrated strategy and a consensus to assess biomarkers, both in academic and industry trials, of the investigations and biomarkers to be explored would greatly enhance efficiency. Tumor biopsies, prior to therapy, with a common portfolio of investigations for DNA sequencing are crucial, in order that the responders and non-responders have similar molecular analyses, helping to validate responder hypotheses." Thus, to be informative, it is mandatory that clinical trials of ATRi have embedded, biocorrelative studies.

Tumor material: The goal should be to collect fresh-frozen tumor tissue (high quality DNA), before entry to trial, in addition to formalin-fixed paraffin-embedded material. Data from paired diagnosis and relapse samples have demonstrated that mutations in certain genes, including proposed biomarkers of ATRi (eg, Death Domain-Associated protein [*DAXX*]), change at the time of relapse,[77,78] as do protein fusions and associated transcription/replication stress, and thus, rebiopsy is required.[79] With interventional radiology, the risks of such biopsies are minimal and should be considered safe and feasible. In several pediatric precision oncology programs such as Stratified Medicine Paediatrics,[54,77,80-82] biopsy at the time of relapse is considered standard of care. The results from biopsies at the time of relapse can identify genomic abnormalities which will guide enrollment on precision medicine trials. Patients and parents are increasingly requesting to be offered the possibility of biopsy at relapse. Patient advocates believed that the probability of obtaining a biopsy before enrollment and at relapse would be increased by ensuring that results are made available to academia, patients, and parents. From an industry perspective, Clinical Laboratory Improvement Amendments and College of American Pathologists validated that confirmation of eligibility is desirable and having material available for a retrospective in-depth study is also supported.

Details of potential biomarkers and their relevance to pediatrics are given in Table 2. The current prioritized investigations are WGS sequencing and transcriptome sequencing, protein expression (ATM, ATRX, RB1, SLFN11, PGBD5, and TP53) detected by immunohistochemistry, and ALT (C-circle and associated promyelocytic leukaemia nuclear bodies-fluorescence in situ hybridization) for high TERT RNA sequencing or reverse transcription-polymerase chain reaction for TERT RNA levels and/or TERT rearrangements) and phosphoproteomic analyses. The objective is to conduct all these investigations; however, in exceptionally small samples, WGS sequencing, transcriptome sequencing, and obtaining circulating tumor DNA should be prioritized.

POTENTIAL COMBINATIONS

There are some data for synthetic lethality of ATR alone, but this can be substantially potentiated by combinations which should be based on, and test, robust biological hypotheses, underpinned by preclinical in vivo data of synergy generated by panels of representative models and/or adult clinical studies and nonoverlapping toxicity. It is crucial that in vivo studies use clinically relevant doses and schedules to inform clinical investigations. There is a strong biological rationale for combinatorial approaches to target DDR and replication including (1) pharmacologically induced replication stress, such as by irinotecan and PARPi; (2) overcoming single-agent resistance[107]; and (3) inducing synthetic lethality in DDR mechanisms.[108] However, there are concerns that synergistic toxicity may require that doses be reduced to levels which are not active, and therefore, toxicity and dose require careful monitoring.

TABLE 1. ATR Inhibitors Evaluated in Patients Younger Than 18 Years

Drug	Combination	Trial/Status	Eligibility (tumor type)	Eligibility (biomarker)	Trial Design	Preliminary Results
Ceralasertib (AstraZeneca)	Olaparib	NCT02813135 ESMART Arm N[69,71]	Relapsed/refractory solid tumors	HR-deficient OR replication/ transcription stress	Phase I—Escalation follows a Bayesian optimal interval design starting at 100% of the adult-optimized dose to determine the RP2D based on the MTD and toxicity and early signals of activity 28-day cycles. Continuous oral dosing: days 1-28 olaparib and days 1-14 ceralasertib followed by expansion cohorts (1) HRR-deficient with a focus on ATM alterations (including 11q loss) (2) Replication stress (*MYC/MYCN* amplification, *CCNE1* amplification, and gene fusions, *EWSR1: FLI1, SSE18: SSX, PAX3/7: FOX01*	N = 18 patients—8 sarcomas, 5 CNS, 4 neuroblastomas, 1 carcinoma 2 PR (neuroblastoma and pineoblastoma), 8 SD 1 neuroblastoma (11q LOH, ATRX VUS) with SD converted to PR, cycle 10 RP2D—olaparib 150 mg twice daily on days 1 to 28 and ceralasertib 80 mg twice daily on days 1-14 for children 12 years and older Main toxicities—hematologic and gastrointestinal (nausea)[67]
Ceralasertib (AstraZeneca)	Olaparib	NCT04417062 [72-74]	Recurrent osteosarcoma		2 cohorts age 12-40 years with recurrent osteosarcoma 1—Unresectable disease and 2—resectable disease limited to the lung receive olaparib 300 mg orally twice a day on days 1-28 and ceralasertib 160 mg orally once a day on days 1-7 of a 28-day cycle	N = 37, 1 ORR
Elimusertib (Bayer)	Monotherapy	NCT05071209 PEPN2112[75,76]	Relapsed/refractory solid tumors	No molecular eligibility for EWS or RMS Other tumors DDR alterations: *ATM ATRX BRCA1, BRCA2, CDK12 CHEK1, CHECK2, FANCA MSH2, MRE11, PALB2, PARP1 POLD1, RAD51, XRCC2*	Initial phase I cohort followed by expansion cohorts: (1) EWS or related EWSR1 fusion—positive tumors (2) Alveolar RMS, PAX3-FOXO1 fusion—positive (3) Non-CNS primary tumors exhibiting specific DDR pathway defects anticipated to sensitize to ATR inhibition	N = 8 patients, 6 evaluable, received adult RP2D of 24 mg/m² per maximum dose (40 mg, with 3 days of drug administration and 4-day rest) No dose-limiting toxicities, pharmacokinetics were similar to adults Trial not designed for dose escalation, to determine the optimal biological dose or MTD (June 2023)[32]

Abbreviations: ANR, active not recruiting; DDR, DNA damage response; EWS, Ewing sarcoma; HRR, homologous recombination repair; MTD, the maximal tolerated dose; OR, objective response; ORR, overall response rate; PR, partial response; RMS, rhabdomyosarcoma; RP2D, recommended phase 2 dose; SD, stable disease; Trial status R, recruiting.

TABLE 2. Details of Potential Biomarkers and Their Relevance to Pediatrics

Investigation	Description	Relevance to Pediatrics
Genomic investigation	Gene panels have very good depth and accuracy; however, they lack breadth, and several genes are not represented on commonly used panels. WES and WGS have good breadth but may not detect specific variants at very low allele frequencies. Rearrangements are included on many fusion panels, but novel fusion partners may be more likely to be detected by RNA or WGS. Notably, some actionable targets may derive from the germline[54,83-85]	Preferred approach would be to have a NGS panel including specific genes of interest to rapidly determine eligibility, followed by retrospective, comprehensive analyses by WGS and RNAseq to identify candidate biomarkers of response and confirm eligibility
Protein investigations	Protein expression can be detected by several assays including immunohistochemistry. ATM, ATRX, RB1, SLFN11, PGBD5, and TP53 are the priority proteins to be measured. Phosphoproteomic analysis will provide greater insight; however, technical issues complicate widespread use and often fresh-frozen tumor material is required.[86] As new platforms for spatial transcriptome and proteome analysis become more available and well-established, these will likely yield valuable information	Immunohistochemistry at present; in the future, spatial transcriptome and proteome analysis
Biomarkers of TMMs	With RNA sequencing, ALT can be identified by a combination of low hTERT and high telomeric repeat containing RNA (TERRA) expression.[87-89] If present, DNA mutations in ATRX and DAXX are almost always associated with ALT activity. However, there are ALT-positive tumors that do not have these mutations. Two investigational ALT-specific assays are ALT-associated PML bodies and c-circles.[87-89] Determination of ALT-associated PML bodies can use FFPE material, but interpretation is subjective and limited by expertise. C-circle assays present various challenges to clinical implementation: (1) ssDNA is unstable at room temperature, (2) fresh-frozen material is required, (3) the tumor material must remain frozen, and (4) the intensity of signal depends on tumor content.[90-92] Real-time PCR assays are being developed to more reliably and reproducibly quantify c-circles	There is no international consensus for ALT determination, and a combination of techniques demonstrating low hTERT expression and an ALT-specific assay should be used
ctDNA	Collection of ctDNA is crucial and should be mandatory as a complementary assay to tissue sequencing; results should also be considered in cases where biopsy is unavailable. The amount of detectable ctDNA may vary across tumor types, with neuroblastoma being the greatest,[93] potentially limiting its applicability. Detection of allelic imbalance can be challenging with low tumor fraction in cell-free DNA[94-98]; however, if there are sufficient ctDNA and a high allele frequency of a relevant mutation, ctDNA is feasible and reliable. By contrast, if a very low allelic fraction of a point mutation is detected, the interpretation can be complicated when the actual tumor fraction is not known	Collection of ctDNA is high priority in view of (1) relative ease of collection, (2) ability to collect serial samples, and (3) reflecting the totality of the disease
DNA mutational signature	DNA mutation signatures of HRR deficiency (eg, HRD BRCAness) have been developed through WES or WGS. Data have recently reported the low prevalence of Signature 3 (COSMIC v3)[80,99] in pediatric tumors	These signatures have not been confirmed in the pediatric clinical setting
Genomic instability signatures	There are several assays to interrogate genomic instability.[100-103] The MyChoice CDx HRD from Myriad Genetics determines a genomic instability score. The Foundation Medicine T5 NGS LOH test only examines loss of heterozygosity and FMI HRD-Sig. In addition, WGS or WES data can be processed by open-source tools, such as scarHRD, to generate a genomic instability score	The utility of these assays for ATRi has not been fully explored nor validated in pediatric populations
Multigene expression signatures	At the RNA level, multigene expression signatures have potential promise as dynamic biomarkers of HRR function and PARPi sensitivity.[104-106]	Highly variable, experience is based on PARP, not ATRi, and no signature has been validated in pediatrics

Abbreviations: ALT, alternative lengthening of telomeres; ctDNA, circulating tumor DNA; FMI, Foundation Medicine Inc; HRD, homologous recombination repair deficiency; HRR, homologous recombination repair; hTERT, human telomerase reverse transcriptase; LOH, loss of heterozygosity; PARP, poly(ADP-ribose) polymerase; PARPi, PARP inhibitors; PCR, polymerase chain reaction; PML, promyelocytic leukemia; ssDNA, single-stranded DNA; TMMs, telomere maintenance mechanisms; WES, whole-exome sequencing; WGS, whole-genome sequencing.

The acute toxicity profile of combinations is very likely to be the same in older children as in adults, but long-term toxicity is difficult to assess.

There are many potential combination partners, which are supported by preclinical investigations (Table 3):

- Novel agents
  - *PARPi.* There is a strong biological rationale for combinations of PARP and ATRi: (1) PARPi create PARP-DNA adducts which stall replication forks; (2) ATR catalytic inhibition interferes with the repair of single-strand breaks, leading to replication fork damage that requires HR repair[112,113]; and (3) ATRi may delay or overcome resistance to PARPi.[48,114-117] Preclinical data, including in neuroblastoma, suggest that the combined inhibition of ATR and PARP is synergistic at sublethal doses.[6,114,115] Concomitant administration of an ATR and PARPi in vitro had a better sustained efficacy than sequential administration.[104,118] In neuroblastoma cells, there is enhanced sensitivity to a PARPi, which may correlate with DDR and replication stress alterations, and this effect is further increased by inhibition of ATR.[6]

- *PARP 1 selective inhibitors* are attractive as they hold promise for reducing myelosuppression and increasing the therapeutic window when used in combination, but this class of agents is early in development.[119,120]

- *ALK inhibitors specific to ALK-aberrant neuroblastoma.* In ALK-mutated, MYCN-amplified models, ALK signaling

TABLE 3. Potential Indications for ATR Inhibitors in Children

Indication	Combination
Molecularly defined indications	
ALK-mutated neuroblastoma	ALK + ATR[109,110]
MYCN-amplified neuroblastoma	Aurora kinase A + ATR[35,111]
Histology-defined populations	
Replication stress EWS fusions, desmoplastic round cell tumor clear cell sarcoma[2] PAX3-FOXO1 fusion[7] Neuroblastoma[6]	PARP + ATR ADC+ ATR Topoisomerase I inhibitors + ATR
Alternative lengthening of telomeres[65-67] Osteosarcoma[88] Neuroblastoma	PARP + ATR ADC + ATR Topoisomerase I inhibitors + ATR
ATRX mutations (eg, osteosarcoma, neuroblastoma, medulloblastoma, high-grade glioma)	PARP + ATR ADC+ ATR Topoisomerase I inhibitors + ATR

NOTE. *ATM* mutation or protein loss/11q loss[45,46] could be an indication, but data are not available, and there are methodological issues with measurement of ATM mutation or protein loss.
Abbreviations: ADC, antibody drug conjugate; ALK, anaplastic lymphoma kinase; PARP, poly(ADP-ribose) polymerase.

leads to phosphorylation of ATR and CHK1 to support an effective DDR, suggesting that combined ALK/ATR inhibition would be superior to monotherapy. In in vivo models, ATR inhibitor monotherapy resulted in a robust initial response, but eventual relapse; however, combinations of ALK inhibitors and ATR inhibitors resulted in a durable response.[109,121]

- *Aurora A kinase (AURKA) inhibitor* (*in MYCN-amplified neuroblastoma*). During the S phase, MYCN protein is stabilized through its physical interaction with AURKA. Pharmacologic inhibition of AURKA is known to inflict transcription-replication stress. Combined inhibition of AURKA and ATR induces extensive tumor-specific apoptosis and tumor regression in *MYCN*-amplified transgenic mouse models.[110,111]
- *Cytotoxic chemotherapy*—Topoisomerase I inhibitors, low-dose cisplatin, and gemcitabine are known to synergize with ATRi.[35,122,123]
- *Antibody drug conjugate (ADC) linked to a topoisomerase I inhibitor payload.* Here, the delivery as an ADC should reduce the toxicity of topoisomerase I inhibition. Trials in adults with HER2 ADCs may be very informative, and new dose-limiting toxicities, for example, lung damage, may be important.[124,125]
- *Combination with WEE1 inhibition and ribonuclease reductase inhibitors are still early in development and may be limited by a potential feedback loop with DNA-PK for CHK1 activation.*[25]

In conclusion, early phase trials in pediatrics of ATRi and ALK inhibitors (in *ALK*-aberrant neuroblastoma), PARP 1 selective inhibitors (in Ewing sarcoma, rhabdomyosarcoma, and other malignancies), and AURKA inhibitors (in

MYCN-amplified neuroblastoma) are required to determine the safety profile and the recommended phase II dose and determine whether there are early signals of activity. Development of these combinations would address current unmet needs.

ATR inhibition influences the immune system and the tumor microenvironment,[109,126,127] potentially leading to further combinations. Specifically, ATR inhibition stimulates the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, recruits T cells (including antigen-specific CD8[+] T cells), and augments the antitumor immune response of PD-L1 blockade. Scheduling of ATRi might have important effects on activity, for example, a short (3 day) course of ATR inhibition, when given with radiotherapy, generates an antigen-specific CD8[+] T-cell response, but this effect is not observed with a more prolonged course of ATR inhibition.[126] This observation should be considered when designing clinical trials.

EARLY PHASE TRIAL DESIGN:

The need for limited monotherapy trials: Strong biological rationale and clinical experience suggest that multiple agents will be more efficacious than monotherapy for most diseases.[128] Preclinically, in Ewing sarcoma[129] and rhabdomyosarcoma,[7] single-agent ATR inhibition only resulted in slowing of growth, and in adult patients, complete loss of ATM was required to achieve clinically relevant synthetic lethality. Molecular profiling from nonresponders to olaparib and irinotecan in arm D of ESMART suggested possible primary resistance to this combination and the potential need for additional ATR inhibition.[130]

It is proposed that early phase trials incorporate limited monotherapy evaluation in a small number of patients to fulfill any regulatory requirements during the initial cycle, to be followed swiftly by a combination in the second cycle.[128] The brief monotherapy evaluation can characterize dose, pharmacokinetics, and toxicity, whereas the intention of the combinatorial approach is to accelerate drug development and maximize the potential for patient benefit. Limited data on monotherapy in children can be complemented with data extrapolated from adults. The results of the phase I/II study of single-agent elimusertib should help inform subsequent studies of ATR.[76] Although scientifically and statistically robust, a randomized trial of an ATRi versus an ATRi and another product is likely not feasible.[131] In most instances, however, the dose of the ATRi in combination will likely be lower than the monotherapy dose because of potential overlapping toxicity. For example, in arm N of ESMART, the ceralasertib and olaparib doses are lower than the maximal tolerated dose of each agent alone but optimized for more continuous exposures and based on adult dosing.[71] Notably, there have been late responses to ATRi seen in pediatric trials and this agrees with studies in adults.

GENERAL STRATEGY

Going forward, there is strong support for the approach taken in ESMART, which includes combination therapy and enrichment for patients with biomarker-positive tumors, but broader eligibility criteria.[70-72,128] There are some histologies (neuroblastoma and translocation-driven sarcomas) that appear to be enriched for susceptibilities to DDR inhibitors. There is strong preliminary evidence that there will not be a single biomarker but rather a constellation of molecular findings, and there are disadvantages to being too stringent in restricting investigations of biomarkers. Analyses should be iterative, and clinical data from studies in adults or pediatric patients and early observations, for example, 11q loss in neuroblastoma, should inform future prospective biomarker selection for trial eligibility. One approach could be to use an adaptive clinical trial platform design that uses a Bayesian statistical model, monitoring response and enriching for the relevant biomarkers as the trial progresses, as has been done in the I-SPY trials.[132] Optimal biomarkers may vary according to the combination of agents and disease subtypes. The adaptive clinical trial platform could be within a master protocol (basket trial). Trials of single ATRi with multiple combination agents are proposed. One of the many strengths of an industry-supported, academic-sponsored platform trial is that assets from different pharmaceutical companies can be included. The platform trial would be conducted to very high-quality standards with intent to file, that is, fit for filling a pediatric investigation plan and early input sought from regulators. It is important to design a complex clinical trial around its primary objective, which should be initially exploratory and hypothesis-generating. Once the trial has generated data, there should be further discussions with regulators on the necessary data needed toward confirmatory evidence (fit for market authorization).[133] With the same eligibility criteria, end points, and methods of patient monitoring, contemporaneous nonrandomized arms can serve as controls.

The current challenge is that despite there are many potential biomarkers, there is difficulty in defining the optimal pediatric screening assay. From an industry viewpoint, defining the population is a critical decision that is often made early. There is a concern that if the approach is too broad, a meaningful response may be diluted. One potential approach is to commence with narrower populations and, if results are encouraging, allow inclusion to become broader. Another strategy is a tissue-agnostic multilayered approach including (1) ATM loss defined by immunochemistry or 11q loss, (2) gene fusions, and (3) ALT by ATRX loss or c-circle assay. However, these groupings are not mutually exclusive as biomarkers might overlap, for example, *ATRX* and 11 q loss. In addition, combinations designed to elicit synthetic lethality or enhance exogenous DNA damage are different mechanistically and will probably have different biomarkers. The major challenge with a histology-agnostic approach is the current lack of established biomarkers. The key will be to evaluate a biomarker both in biomarker-positive and biomarker-negative populations and then revise the biomarker hypothesis. As such, an industry-supported, academic-sponsored international platform trial that provides clinical trial data that can be used for licensing purposes—fit for filing—would be a highly efficient approach to evaluate ATRi in the pediatric population. These concepts were discussed and endorsed at a recent meeting in the Childhood Cancer Academic-Industry Collaborative: Platform Trials of the Multi-Regional Clinical Trials Center (MRCT Center), Brigham, and Women's Hospital and Harvard University, in Boston.[133]

OVERALL PLAN FOR DEVELOPMENT

In very rare patient populations, overlap of clinical studies evaluating similar drugs for the same clinical indications needs to be avoided; otherwise, the same hypothesis will be addressed repeatedly, knowledge will not be advanced, and trials will fail to recruit. Clinical trials, driven by regulatory requirements, should fulfill patient needs.[134-136] A coordinated and integrated drug development strategy is required when developing multiple products of the same class in a rare group of children.[134-136] One approach is to encourage industry partners to develop different products within the same class for different indications. For example, there is strong preclinical evidence for combinations of ATRi with PARP, ALK, and aurora kinase A inhibitors in neuroblastoma. One proposal is that the academic early phase cooperative groups help guide companies to potential nonoverlapping indications. For example cooperative groups, suggest one company evaluates a combination with PARPi, another a combination with an ALK inhibitor and a further with an aurora A kinase inhibitor. Another approach is a focused and sequential development. For this approach to work, there should be agreement by all involved (industry and academia) through external agencies, on which product(s) based on current evidence should be advanced first for regulatory approval, without delay. The sequence (based on scientific arguments) for other available or emerging products should be agreed upon, and as soon as the development of the first product is completed (either because of futility or efficacy), other products should already be prepared to be evaluated.[18,135] Academic-sponsored platform trials, such as ESMART, ComboMATCH, and Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL),[69,71,128,137-139] can evaluate different combinations of different products from different companies.

Despite recent or impending major regulatory developments, the challenge remains that pediatric drug development is driven by adult indications. There is reluctance for companies to evaluate a new class of medicinal products in pediatrics until they have identified an adult indication and started the process to submit a New Drug Application or Biologics License Application with a route forward to market authorization. Given the legislative mandate for pediatric evaluation of compounds directed at a molecular target

which is relevant to the growth or progression of a pediatric cancer, regulators should be encouraged when there is intense investigator interest based on evidence to entertain discussions with industry sponsors about possible pediatric investigation as early as possible in the development timeline of appropriate molecules, rather than limiting pediatric discussion plans contingent upon a decision for the adult indication for which they plan to seek approval. Importantly, proof of concept from adult studies may not be relevant to pediatric studies as the mechanism of action may be different. Currently, this is the situation with ATRi. For example, there are a strong mechanism of action and preclinical evidence supporting combining ATRi with ALK inhibitors in *ALK/MYCN*-aberrant neuroblastoma, where there is an unmet need for new therapies. Yet, companies are reluctant to provide ATRi for these trials as there is no adult indication for a market authorization. To enhance the early evaluation and development of ATRi in children and make this attractive to industry, early phase investigation clinical trials should be conducted in regulatory-approved, academic-sponsored, industry-supported, platform trials, which have been designed so that data produced can be used for regulatory purposes. In Europe, the European Medicines Agency (EMA) supports this via scientific advice, and such a platform can be used in a pediatric investigation plan to generate evidence supporting clinical proof of concept (eg, early go/no go decision making) such that only the most promising product(s) move toward evidence generation, supporting a registration.[140] An example is the Glo-BNHL study where the EMA, not part of Glo-BNHL, provided qualification advice with a letter of support on its website on the methodological and scientific aspects, endorsing the trial. This has facilitated the development of products for B-cell lymphoma, and companies have used the platform for regulatory purposes. Such a platform could provide benefits and efficiencies to industry, with a clear value proposition supporting development efforts.

To rapidly advance knowledge, protect patients, and avoid redundancy (which can hinder enrollment because of scarcity of patients), global coordination of early development and late development programs across multiple agents in the same class is necessary. The objective is to drive timely pediatric development through scientific, data-driven approaches that maximize the potential to address unmet medical needs, generate robust clinical evidence, and elucidate a biomarker hypothesis. Class, product and combination prioritization are needed to ensure that patients enrolling in trials have the best chance of benefiting from investigational treatment. A framework to support integrated development strategies of new products like the ATRi across sponsors would be very beneficial.

AFFILIATIONS

[1]Department of Cancer and Genomic Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom
[2]Department of Paediatric Oncology, Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
[3]Memorial Sloan Kettering Cancer Centre, New York, NY
[4]ACCELERATE, Brussels, Belgium
[5]Genentech, A Member of the Roche Group, South San Francisco, CA
[6]Institute of Cancer Research, Sutton, United Kingdom
[7]Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom
[8]Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada
[9]Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ
[10]Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
[11]Cancer Research Institute Ghent (CRIG), Ghent, Belgium
[12]Department of Oncology, St Jude Children's Research Hospital, Memphis, TN
[13]The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
[14]Merck Serono Ltd, Feltham, United Kingdom, an affiliate of Merck KGaA, Darmstadt, Germany
[15]Charité—Universitätsmedizin, Berlin, Germany
[16]Princess Máxima Center for Pediatric oncology, Utrecht, the Netherlands
[17]University Medical Center Utrecht (UMCU), Utrecht, the Netherlands
[18]Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany
[19]German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
[20]AstraZeneca, Cambridge, United Kingdom
[21]Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
[22]EMD Serono, Billerica, MA
[23]Hopp Children's Cancer Center Heidelberg (KiTZ)/Division of Pediatric Neurooncology, DKFZ/KiTZ, Clinical Trial Unit and Childhood Brain Tumors, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany
[24]National Cancer Institute, Bethesda, MD
[25]Gustave Roussy Cancer Centre, Paris, France

CORRESPONDING AUTHOR

Andrew D.J. Pearson, MBBS, MD, DCH; e-mail: andy1pearson@btinternet.com.

DISCLAIMER

Andrew McDonough B+ Foundation for financial support of ACCELERATE.

EQUAL CONTRIBUTION

S.A.G., J.G.-B., A.D.J.P., and M.V.O. are joint first authors.

AUTHOR CONTRIBUTIONS

Conception and design: Susanne A. Gatz, Julia Glade-Bender, Andrew D.J. Pearson, Michael V. Ortiz, Sarah Cohen-Gogo, Esther De La Cuesta, Teresa de Rojas, Elizabeth Fox, Ioannis Gounaris, Anton George

Henssen, Alberto Pappo, Gregory K. Pennock, Emily K. Slotkin, Malcolm Smith, Brenda J. Weigel, Gilles Vassal

Administrative support: Alberto Pappo

Provision of study materials or patients: Lou Chesler, Alan Lau, Frank Speleman

Collection and assembly of data: Andrew D.J. Pearson, Michael V. Ortiz, Ronald Bernardi, Sarah Cohen-Gogo, Teresa de Rojas, Kaat Durinck, Anton George Henssen, Meredith Irwin, Alan Lau, Frank Speleman

Data analysis and interpretation: Susanne A. Gatz, Julia Glade-Bender, Andrew D.J. Pearson, Michael V. Ortiz, Ronald Bernardi, Lou Chesler, Steve Clifford, Sarah Cohen-Gogo, Teresa de Rojas, Kaat Durinck, Sara Federico, Elizabeth Fox, Sally George, Ioannis Gounaris, Anton George Henssen, Meredith Irwin, Marcel Kool, Karsten Nysom, Stefan M. Pfister, Nicole Scobie, Frank Speleman, Elizabeth A. Stewart, Brenda J. Weigel

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Susanne A. Gatz
Consulting or Advisory Role: Amgen, Gilead Sciences, AstraZeneca
Research Funding: AstraZeneca (Inst), GlaxoSmithKline (Inst), Bayer (Inst), AstraZeneca (Inst)

Julia Glade-Bender
Consulting or Advisory Role: Jazz Pharmaceuticals
Research Funding: Eisai (Inst), Lilly (Inst), Loxo (Inst), Roche/Genentech (Inst), Bayer (Inst), Jazz Pharmaceuticals (Inst), Jazz Pharmaceuticals (Inst), Merck (Inst)
Patents, Royalties, Other Intellectual Property: Patent on a T lymphoblastic lymphoma cell line, CUTLL1
Travel, Accommodations, Expenses: Amgen (Inst), Eisai (Inst)
Uncompensated Relationships: SpringWorks Therapeutics, Bristol Myers Squibb, Merck, Eisai, Pfizer
Open Payments Link: https://openpaymentsdata.cms.gov/physician/708514

Andrew D.J. Pearson
Honoraria: Norgine
Consulting or Advisory Role: Norgine

Ronald Bernardi
Employment: Genentech/Roche, Exelixis
Stock and Other Ownership Interests: Roche/Genentech, Exelixis

Lou Chesler
Consulting or Advisory Role: Abbvie

Esther De La Cuesta
Employment: Bayer
Stock and Other Ownership Interests: Bayer
Travel, Accommodations, Expenses: Bayer

Sally George
Travel, Accommodations, Expenses: Recordati

Ioannis Gounaris
Employment: Merck Serono
Stock and Other Ownership Interests: Novartis, Alcon, Sandoz

Anton George Henssen
Stock and Other Ownership Interests: Econic Biosciences
Consulting or Advisory Role: Econic Biosciences
Research Funding: Bayer

Alan Lau
Employment: AstraZeneca
Stock and Other Ownership Interests: AstraZeneca
Patents, Royalties, Other Intellectual Property: I am named on patents filed by AstraZeneca plc., but do not receive royalties

Karsten Nysom
Consulting or Advisory Role: Lilly, Ipsen

Alberto Pappo
Honoraria: Bayer, Roche, Lilly, Pfizer
Consulting or Advisory Role: Merck, Loxo/Bayer, EUSA Pharma, Debbio, Lilly, Pfizer

Gregory K. Pennock
Employment: EMD Serono

Stefan M. Pfister
Leadership: PMC, University Hospital Essen Westdeutsches Tumorzentrum
Stock and Other Ownership Interests: Heidelberg Epignostix
Consulting or Advisory Role: BioSkryb
Research Funding: Lilly (Inst), Bayer (Inst), Roche (Inst), PharmaMar (Inst), Pfizer (Inst), AstraZeneca (Inst), Janssen & Janssen (Inst), Servier (Inst), Sanofi (Inst), Amgen (Inst)
Patents, Royalties, Other Intellectual Property: Patent on utilizing DNA methylation profiling for tumor classification, patent using nanopore sequencing for rapid tumor diagnostics, Rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept study, Method for the detection of a premalignant lesion in a subject

Emily K. Slotkin
Consulting or Advisory Role: Guidepoint Global, Inhibrx
Research Funding: Lilly (Inst), Esperas Pharma

Gilles Vassal
Consulting or Advisory Role: AstraZeneca, Pfizer, Abbvie, Merck, Daiichi Sankyo/Astra Zeneca, SERVIER

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT

REFERENCES

1. Ngoi NYL, Pilié PG, McGrail DJ, et al: Targeting ATR in patients with cancer. Nat Rev Clin Oncol 21:278-293, 2024
2. Bradbury A, Hall S, Curtin N, et al: Targeting ATR as cancer therapy: A new era for synthetic lethality and synergistic combinations? Pharmacol Ther 207:107450, 2020
3. Stewart E, Goshorn R, Bradley C, et al: Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep 9:829-841, 2014
4. Gorthi A, Romero JC, Loranc E, et al: EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature 555:387-391, 2018
5. Rodriguez-Fos E, Planas-Fèlix M, Burkert M, et al: Mutational topography reflects clinical neuroblastoma heterogeneity. Cell Genom 3:100402, 2023
6. Hayes MN, Cohen-Gogo S, Kee L, et al: DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition. Cell Rep 44:115537, 2025

7. Dorado García H, Pusch F, Bei Y, et al: Therapeutic targeting of ATR in alveolar rhabdomyosarcoma. Nat Commun 13:4297, 2022
8. Li X, Dean DC, Cote GM, et al: Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma. Ther Adv Med Oncol 12: 1758835920956900, 2020
9. Oberg JA, Glade BenderJL, Sulis ML, et al: Implementation of next generation sequencing into pediatric hematology-oncology practice: Moving beyond actionable alterations. Genome Med 8:133, 2016
10. Vassal G, Rousseau R, Blanc P, et al: Creating a unique, multi-stakeholder Paediatric Oncology platform to improve drug development for children and adolescents with cancer. Eur J Cancer 51: 218-224, 2015
11. Pearson ADJ, Weiner SL, Adamson PC, et al: ACCELERATE - Five years accelerating cancer drug development for children and adolescents. Eur J Cancer 166:145-164, 2022
12. Pearson ADJ, Federico S, Gatz SA, et al: Paediatric strategy forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer 190:112950, 2023
13. O'Connor MJ: Targeting the DNA damage response in cancer. Mol Cell 60:547-560, 2015
14. Blackford AN, Jackson SP: ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response. Mol Cell 66:801-817, 2017
15. Trenner A, Sartori AA: Harnessing DNA double-strand break repair for cancer treatment. Front Oncol 9:1388, 2019
16. Zeman MK, Cimprich KA: Causes and consequences of replication stress. Nat Cell Biol 16:2-9, 2014
17. Kotsantis P, Petermann E, Boulton SJ: Mechanisms of oncogene-induced replication stress: Jigsaw falling into place. Cancer Discov 8:537-555, 2018
18. Saldivar JC, Cortez D, Cimprich KA: The essential kinase ATR: Ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 18:622-636, 2017
19. Bass TE, Luzwick JW, Kavanaugh G, et al: ETAA1 acts at stalled replication forks to maintain genome integrity. Nat Cell Biol 18:1185-1195, 2016
20. Haahr P, Hoffmann S, Tollenaere MA, et al: Activation of the ATR kinase by the RPA-binding protein ETAA1. Nat Cell Biol 18:1196-1207, 2016
21. Buisson R, Boisvert JL, Benes CH, et al: Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase. Mol Cell 59:1011-1024, 2015
22. Karnitz LM, Zou L: Molecular pathways: Targeting ATR in cancer therapy. Clin Cancer Res 21:4780-4785, 2015
23. Buisson R, Niraj J, Rodrigue A, et al: Coupling of homologous recombination and the checkpoint by ATR. Mol Cell 65:336-346, 2017
24. Macheret M, Halazonetis TD: DNA replication stress as a hallmark of cancer. Annu Rev Pathol 10:425-448, 2015
25. Nunes C, Depestel L, Mus L, et al: RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. Sci Adv 8:eabn1382, 2022
26. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005
27. Mateo J, Lord CJ, Serra V, et al: A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 30:1437-1447, 2019
28. Pilié PG, Tang C, Mills GB, et al: State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 16:81-104, 2019
29. Murga M, Bunting S, Montaña MF, et al: A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet 41:891-898, 2009
30. Lee Y, Brown EJ, Chang S, et al: Pot1a prevents telomere dysfunction and ATM-dependent neuronal loss. J Neurosci 34:7836-7844, 2014
31. Kim J, Choi I, Lee Y: Involvement of Atm and Trp53 in neural cell loss due to Terf2 inactivation during mouse brain development. Histochem Cell Biol 148:489-501, 2017
32. Peasland A, Wang LZ, Rowling E, et al: Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 105:372-381, 2011
33. Cote GM, Kochupurakkal BS, Do K, et al: A translational study of the ATR inhibitor berzosertib as monotherapy in four molecularly defined cohorts of advanced solid tumors. Clin Cancer Res 31: 35-44, 2025
34. Konstantinopoulos PA, Cheng SC, Lee EK, et al: Randomized phase II study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival and biomarker analyses. JCO Precis Oncol 10.1200/PO.23.00635
35. Wilson Z, Odedra R, Wallez Y, et al: ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib. Cancer Res 82:1140-1152, 2022
36. Yap TA, Krebs MG, Postel-Vinay S, et al: Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: A phase I study. Clin Cancer Res 27:5213-5224, 2021
37. Yap TA, Tan DSP, Terbuch A, et al: First-in-Human trial of the oral ataxia telangiectasia and RAD3- related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov 11: 80-91, 2021
38. Krishnamurthy A, Wang H, Rhee JC, et al: Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406). Cancer Chemother Pharmacol 5:27, 2025
39. Fontana E, Rosen E, Lee EK, et al: Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). J Natl Cancer Inst 116:1439-1449, 2024
40. Yap TA, Fontana E, Lee EK, et al: Camonsertib in DNA damage response-deficient advanced solid tumors: Phase 1 trial results. Nat Med 29:1400-1411, 2023
41. Yap TA, Tolcher AW, Plummer R, et al: First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors. Clin Cancer Res 30:2057-2067, 2024
42. Moore K, Patel MR, Falchook GS, et al: First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors. Ann Oncol 34:S475-S476, 2024
43. Yap TA, O'Carrigan B, Penney MS, et al: Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol 38:3195-3204, 2020
44. Dillon MT, Guevara J, Mohammed K, et al: Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest 134:e175369, 2024
45. Yap TA, Tan DSP, Stathis A, et al: Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects. Cancer Discov 15:2019-2035, 2025
46. Rafiei S, Fitzpatrick K, Liu D, et al: ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer. Cancer Res 80:2094-2100, 2020
47. da Costa AABA, Chowdhury D, Shapiro GI, D'Andrea AD, Konstantinopoulos PA: Targeting replication stress in cancer therapy. Nat Rev Drug Discov 22:38-58, 2023
48. Murai J, Feng Y, Yu GK, et al: Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 7:76534-76550, 2016
49. Kwon M, Kim G, Kim R, et al: Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. Immunother Cancer 10:e005041, 2022
50. Kim R, Kwon M, An M, et al: Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann Oncol 33:193-203, 2022
51. Gröbner SN, Worst BC, Weischenfeldt J, et al: The landscape of genomic alterations across childhood cancers. Nature 555:321-327, 2018
52. Wong M, Mayoh C, Lau LMS, et al: Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med 26:1742-1753, 2020
53. Newman S, Nakitandwe J, Kesserwan CA, et al: Genomes for kids: The scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing. Cancer Discov 11:3008-3027, 2021
54. Berlanga P, Pierron G, Lacroix L, et al: The European MAPPYACTS trial: Precision medicine program in pediatric and adolescent patients with recurrent malignancies. Cancer Discov 12: 1266-1281, 2022
55. Parsons DW, Janeway KA, Patton DR, et al: Actionable tumor alterations and treatment protocol enrollment of pediatric and young adult patients with refractory cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH trial. J Clin Oncol 40:2224-2234, 2022
56. Setton J, Zinda M, Riaz N, et al: Synthetic lethality in cancer therapeutics: The next generation. Cancer Discov 11:1626-1635, 2021
57. Weigelt B, Bi R, Kumar R, et al: The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers. J Natl Cancer Inst 110:130-1034, 2018
58. Sanmartín E, Muñoz L, Piqueras M, et al: Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition. Clin Cancer Res 23:6875-6887, 2017
59. King D, Li XD, Almeida GS, et al: MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma. Oncotarget 11:2141-2159, 2020
60. Schoppy DW, Ragland RL, Gilad O, et al: Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest 122:241-252, 2012
61. Sun Z, Zhang Z, Wang QQ, et al: Combined inactivation of CTPS1 and ATR is synthetically lethal to MYC-overexpressing cancer cells. Cancer Res 82:1013-1024, 2022
62. Pusch FF, Dorado García H, Xu R, et al: Elimusertib has antitumor activity in preclinical patient-derived pediatric solid tumor models. Mol Cancer Ther 23:507-519, 2024
63. Koppenhafer SL, Goss KL, Terry WW, et al: Inhibition of the ATR-CHK1 pathway in ewing sarcoma cells causes DNA damage and apoptosis via the CDK2-Mediated degradation of RRM2. Mol Cancer Res 18:91-104, 2020
64. Sobinoff AP, Pickett HA: Alternative lengthening of telomeres: DNA repair pathways converge. Trends Genet 33:921-932, 2017
65. Flynn RL, Cox KE, Jeitany M, et al: Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347:273-277, 2015
66. Deeg KI, Chung I, Bauer C, et al: Cancer cells with alternative lengthening of telomeres do not display a general hypersensitivity to ATR inhibition. Front Oncol 6:186, 2016
67. Akter J, Katai Y, Sultana P, et al: Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma. Oncogenesis 10:73, 2021

68. Koneru B, Farooqi A, Nguyen TH, et al: ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156. Sci Transl Med 13: eabd5750, 2021

69. European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART). clinicaltrials.gov/study/NCT02813135

70. Geoerger B, Paoletti X, Bautista F, et al: AcSe-ESMART, a European precision cancer medicine proof-of-concept platform trial. Nat Med 29:2985-2987, 2023

71. Gatz SA, San Simón AR, Archambaud B, et al: Phase I/II study of the PARP inhibitor olaparib and ATR inhibitor ceralasertib in children with advanced malignancies: Arm N of the AcSé-ESMART trial. Cancer Res 83, 2023 (suppl 8; abstr CT019)

72. Olaparib With Ceralasertib in Recurrent Osteosarcoma. https://clinicaltrials.gov/study/NCT04417062

73. Forrest SJ, Kinnaman MD, Livingston JA, et al: Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma. J Clin Oncol 39, 2023 (suppl 15; abstr TPS11575)

74. Forrest F, Livingston J, Vo K, et al: Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma. J Clin Oncol 43, 2025 (suppl 16; abstr 10005)

75. Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors. https://clinicaltrials.gov/study/NCT05071209

76. Ortiz MV, Glade Bender JL, Minard CG, et al: A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112. J Clin Oncol 41, 2023 (suppl 15; abstr e15131)

77. George SL, Lynn C, Stankunaite R, et al: Stratified medicine paediatrics: Cell free DNA and serial tumour sequencing identifies subtype specific cancer evolution and epigenetic states. Cancer Discov 15:717-732, 2025

78. Jo U, Murai Y, Takebe N, et al: Precision oncology with drugs targeting the replication stress, ATR, and schlafen 11. Cancers (Basel) 13:4601, 2021

79. de Traux de Wardin H, Dermawan JK, Merlin MS, et al: Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression and relapse. NPJ Precis Oncol 7:96, 2023

80. Villani A, Davidson S, Kanwar N, et al: The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations. Nat Cancer 4:203-221, 2023

81. Harris MH, DuBois SG, Glade Bender JL, et al: Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: The individualized cancer therapy (iCat) study. JAMA Oncol 2:608-615, 2016

82. Lau LMS, Khuong-Quang DA, Mayoh C, et al: Precision-guided treatment in high-risk pediatric cancers. Nat Med 30:1913-1922, 2024

83. Shukla N, Levine MF, Gundem G, et al: Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. Nat Commun 13:2485, 2022

84. Langenberg KPS, Meister MT, Bakhuizen JJ, et al: Implementation of paediatric precision oncology into clinical practice: The individualized therapies for children with cancer program 'iTHER. Eur J Cancer 175:311-325, 2022

85. Hodder A, Leiter SM, Kennedy J, et al: Benefits for children with suspected cancer from routine whole-genome sequencing. Nat Med 30:1905-1912, 2024

86. Dakup PP, Feng S, Shi T, et al: Targeted quantification of protein phosphorylation and its contributions towards mathematical modeling of signaling pathways. Molecules 28:1143, 2023

87. Meeser A, Bartenhagen C, Werr L, et al: Reliable assessment of telomere maintenance mechanisms in neuroblastoma. Cell Biosci 12:160, 2022

88. Burrow TA, Koneru B, Macha SJ, et al: Prevalence of alternative lengthening of telomeres in pediatric sarcomas determined by the telomeric DNA C-circle assay. Front Oncol 14:1399442, 2024

89. Lau LM, Dagg RA, Henson JD, et al: Detection of alternative lengthening of telomeres by telomere quantitative PCR. Nucleic Acids Res 41:e34, 2013

90. Henson JD, Cao Y, Huschtscha LI, et al: DNA C-circles are specific and quantifiable markers of alternative lengthening-of-telomeres activity. Nat Biotechnol 27:1181-1185, 2009

91. Idilli AI, Segura-Bayona S, Lippert TP, et al: A C-circle assay for detection of alternative lengthening of telomere activity in FFPE tissue. STAR Protoc 2:100569, 2021

92. Henson JD, Lau LM, Koch S, et al: The C-circle assay for alternative-lengthening-of-telomeres activity. Methods 114:74-84, 2017

93. Ek T, Ibrahim RR, Vogt H, et al: Long-lasting response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma monitored with circulating tumor DNA analysis. Cancer Res Commun 4:2553-2564, 2024

94. Stankunaite R, George SL, Gallagher L, et al: Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. Eur J Cancer 162:209-220, 2022

95. Berko ER, Witek GM, Matkar S, et al: Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma. Nat Commun 14:2601, 2023

96. Bobin C, Iddir Y, Butterworth C, et al: Sequential analysis of cfDNA reveals clonal evolution in neuroblastoma patients receiving ALK targeted therapy. Clin Cancer Res 30:3316-3328, 2024

97. Tivey A, Church M, Rothwell D, et al: Circulating tumour DNA - Looking beyond the blood. Nat Rev Clin Oncol 19:600-612, 2022

98. Pascual J, Attard G, Bidard FC, et al: ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group. Ann Oncol 33:750-768, 2022

99. Thatikonda V, Islam SMA, Autry RJ, et al: Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. Nat Cancer 4:276-289, 2023

100. Dreyer SB, Upstill-Goddard R, Paulus-Hock V, et al: Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology 160:362-377, 2021

101. Guerrero LS, Bhattacharya A, Everts M, et al: An mRNA expression-based signature for oncogene-induced replication-stress. Oncogene 41:1216-1224, 2022

102. Takahashi N, Kim S, Schultz CW, et al: Share replication stress defines distinct molecular subtypes across cancers. Cancer Res Commun 2:503-517, 2022

103. Barnicle A, Ray-Coquard I, Rouleau E, et al: Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib. Genome Med 16:145, 2024

104. Zimmermann M, Bernier C, Kaiser B, et al: Guiding ATR and PARP inhibitor combinations with chemogenomic screens. Cell Rep. 40:111081, 2022

105. Wang C, Wang G, Feng X, et al: Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. Oncogene 38:2451-2463, 2019

106. Hustedt N, Álvarez-Quilón A, McEwan A, et al: A consensus set of genetic vulnerabilities to ATR inhibition. Open Biol 9:190156, 2019

107. Cybulla E, Vindigni A: Leveraging the replication stress response to optimize cancer therapy. Nat Rev Cancer 23:6-24, 2023

108. Li Q, Qian W, Zhang Y, et al: A new wave of innovations within the DNA damage response. Signal Transduct Target Ther 8:338, 2023

109. Borenäs M, Umapathy G, Lind DE, et al: ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition. Proc Natl Acad Sci U S A. 121: e2315242121, 2024

110. Otto T, Horn S, Brockmann M, et al: Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15:67-78, 2009

111. Roeschert I, Poon E, Henssen AG, et al: Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma. Nat Cancer 2:312-326, 2021

112. Murai J, Huang SY, Das BB, et al: Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72:5588-5599, 2012

113. Canman CE: Which holds the key to BRCAness: Inability to repair the break, protect the fork, or prevent the gap? Cancer Res 81:1214-1215, 2021

114. Kim H, George E, Ragland R, et al: Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin Cancer Res 23:3097-3108, 2017

115. Lloyd RL, Wijnhoven PWG, Ramos-Montoya A, et al: Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene 39:4869-4883, 2020

116. Schoonen PM, Talens F, Stok C, et al: Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. Nat Commun 8:15981, 2017

117. Yazinski SA, Comaills V, Buisson R, et al: ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev 31:318-332, 2017

118. Roulston A, Zimmermann M, Papp R, et al: A novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors. Mol Cancer Ther 21:245-256, 2022

119. Johannes JW, Balazs A, Barratt D, et al: Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl) methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs. J Med Chem 64:14498-14512, 2021

120. Yap TA, Im S-A, Schram AM, et al: CT007 - PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations. Cancer Res 82:CT007, 2022

121. Szydzik J, Lind DE, Arefin B, et al: ATR inhibition enables complete tumour regression in ALK-driven NB mouse models. Nat Commun 12:6813, 2021

122. Ohmura S, Grünewald TGP: Optimizing ATR inhibition and cisplatin synergy in ewing sarcoma. Clin Cancer Res 30:3358-3360, 2024

123. Höfer S, Frasch L, Brajkovic S, et al: Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response. Mol Syst Biol 21:231-253, 2025

124. Abel ML, Takahashi N, Peer C, et al: Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: A phase I clinical trial. Clin Cancer Res 29:3603-3611, 2023

125. Li Y, Li L, Fu H, et al: Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers. Am J Cancer Res 13:161-175, 2023

126. Vendetti FP, Pandya P, Clump DA, et al: The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. JCI Insight 8:e165615, 2023

127. Taniguchi H, Chakraborty S, Takahashi N, et al: ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Sci Adv 10: eado4618, 2024

128. Moreno L, DuBois SG, Glade Bender J, et al: Combination early-phase trials of anticancer agents in children and adolescents. J Clin Oncol 41:3408-3422, 2023

129. Nieto-Soler M, Morgado-Palacin I, Lafarga V, et al: Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget:758759-758767, 2016

130. Geoerger B, Bautista F, André N, et al: Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART. Eur J Cancer 208:114201, 2024

131. Bird N, Scobie N, Berlanga P, et al: Stakeholder perspectives on randomized clinical trials for children with poor-prognosis cancers. JAMA Netw Open 7:e2449239, 2024

132. Wang H, Yee D: I-SPY 2: A neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer. Curr Breast Cancer Rep 11:303-331, 2019

133. Childhood Cancer Academic-Industry Collaborative: Platform Trials. https://mrctcenter.org/platform-oncology

134. Pearson ADJ, Kolb EA, Zwaan CM, et al: Paediatric strategy forum for medicinal product development for acute myeloid leukaemia in children and adolescents. Eur J Cancer 136:116-129, 2020

135. Pearson AD, DuBois SG, Macy ME, et al: Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer. Eur J Cancer 207:114145, 2024

136. Pearson AD, DuBois SG, Buenger V, et al: Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Eur J Cancer 146:115-124, 2021

137. Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, the ComboMATCH Screening Trial. https://clinicaltrials.gov/study/NCT05564377

138. Harris LN, Blanke CD, Erba HP, et al: The new NCI precision medicine trials. Clin Cancer Res 29:4728-4732, 2023

139. A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL). https://clinicaltrials.gov/study/NCT05991388

140. Karres D, Lesa G, Ligas F, et al: European regulatory strategy for supporting childhood cancer therapy developments. Eur J Cancer 177:25-29, 2022